Pharsight

1. List of Carnexiv drug patents

Application	Filing Date	Opposition Party	Legal Status
EP06816054A	2015-02-06	Actavis Group PTC ehf	Revoked

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US9770407	December, 2014	Decision	Lundbeck Pharmaceuticals LLC
US9629797	July, 2014	Decision	James Cloyd et al

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9770407	LUNDBECK PHARMS LLC	Parenteral carbamazepine formulation	Nov, 2028 (5 years from now)
US9629797	LUNDBECK PHARMS LLC	Parenteral carbamazepine formulation	Nov, 2028 (5 years from now)
US8410077	LUNDBECK PHARMS LLC	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (5 years from now)
US7635773	LUNDBECK PHARMS LLC	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (5 years from now)
US9750822	LUNDBECK PHARMS LLC	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (5 years from now)
US9493582	LUNDBECK PHARMS LLC	Alkylated cyclodextrin compositions and processes for preparing and using the same	Feb, 2033 (9 years from now)
US11529357	LUNDBECK PHARMS LLC	Injectable carbamazepine composition essentially free of 10-bromo-carbamazepine	Jan, 2040 (16 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Oct 7, 2023

Drugs and Companies using CARBAMAZEPINE ingredient

Market Authorisation Date: 07 October, 2016

Treatment: Replacement therapy for oral carbamazepine in adults with partial seizures with complex symptomatology; Replacement therapy for oral carbamazepine in adults with generalized tonic-clonic seizures; Replacement therapy for oral carbamazepine in adults with mixed seizure patterns that include partial seizures with complex symptomatology, generalized tonic-clonic seizures, or other partial or generalized seizures

Dosage: SOLUTION;INTRAVENOUS